title: [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].
abstract: OBJECTIVE
  To assess the activity and toxicity of gemcitabine in locally advanced or metastatic soft tissue sarcoma patients (pts).
  
  
  METHODS
  Gemcitabine was administered on days 1, 8, 15 every 4 weeks at a dose of 1.000/1.250 mg/m2, respectively, in pretreated or not pretreated pts.
  
  
  RESULTS
  Eighteen pts entered this phase II trial; sixteen had been previously treated with anthracyclines and ifosfamide. A partial response was observed in a woman with fibrous malignant istocytoma, whereas in 7 pts the disease remained stable. Median time to progression was 4 months. The treatment was well tolerated. Grade 4 toxicity was not observed.
  
  
  CONCLUSIONS
  These results do not suggest that gemcitabine, in the dose and schedule used in this trial, may be of value in the treatment of soft tissue sarcomas.
authors.affiliation: Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
authors.forename: A
authors.initials: A
authors.lastname: Amodio
authors.forename: S
authors.initials: S
authors.lastname: Carpano
authors.forename: C
authors.initials: C
authors.lastname: Manfredi
authors.forename: G
authors.initials: G
authors.lastname: Del Monte
authors.forename: L
authors.initials: L
authors.lastname: Di Lauro
authors.forename: T
authors.initials: T
authors.lastname: Gionfra
authors.forename: F
authors.initials: F
authors.lastname: Conti
authors.forename: G
authors.initials: G
authors.lastname: Paoletti
authors.forename: M
authors.initials: M
authors.lastname: Lopez
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
vernacular_title: Gemcitabina nei sarcomi dei tessuti molli in fase avanzata: studio di fase II.